A curious case of pulmonary hypertension in a child

A Shaheer Ahmed1, Gaurav Kumar Divani2, Shivank Gupta2

  • 1Department of Cardiology, Vardhman Mahavir Medical College and Safdarjung Hospital, 7th floor, Super speciality block, New Delhi, 110029, India. ahmedshaheer53@gmail.com.

Insights

Constrictive pericarditis can cause severe pulmonary hypertension in children, mimicking idiopathic pulmonary hypertension. Early diagnosis and treatment of reversible causes like constrictive pericarditis are crucial for better outcomes.

Area of Science:

  • Pediatric Cardiology
  • Pulmonary Hypertension
  • Cardiothoracic Surgery

Background:

  • Pulmonary hypertension in children has diverse causes, some reversible.
  • Idiopathic pulmonary hypertension is a diagnosis of exclusion.
  • Prompt identification of treatable etiologies is essential.

Purpose of the Study:

  • To report a rare case of pulmonary hypertension secondary to constrictive pericarditis in a child.
  • To highlight the importance of considering reversible causes of pulmonary hypertension.

Main Methods:

  • A 12-year-old boy with exertional dyspnea and fatigue was re-evaluated for presumed primary pulmonary hypertension.
  • Diagnostic workup included a detailed clinical assessment and investigations leading to constrictive pericarditis diagnosis.
  • The patient was referred for surgical management (pericardiectomy).

Main Results:

  • Constrictive pericarditis was identified as the cause of severe pulmonary hypertension.
  • The patient's symptoms were initially misattributed to idiopathic pulmonary hypertension.
  • The diagnosis was confirmed, and surgical intervention was planned.

Conclusions:

  • Constrictive pericarditis can present with severe pulmonary hypertension without typical congestive heart failure symptoms.
  • This case underscores the need to exclude reversible causes before diagnosing idiopathic pulmonary hypertension.
  • Thorough evaluation is critical for accurate diagnosis and management of pediatric pulmonary hypertension.
Abstract

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
275
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
315
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
42
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
247
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
240
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.8K